Jane Street Group LLC Takes $46,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Jane Street Group LLC acquired a new stake in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 29,580 shares of the biopharmaceutical company’s stock, valued at approximately $46,000.

Other institutional investors have also recently made changes to their positions in the company. Creative Planning acquired a new position in shares of Regulus Therapeutics during the third quarter valued at about $26,000. SG Americas Securities LLC bought a new stake in Regulus Therapeutics in the 3rd quarter worth about $33,000. Rhumbline Advisers bought a new stake in Regulus Therapeutics in the 2nd quarter worth about $136,000. Tyche Wealth Partners LLC grew its position in Regulus Therapeutics by 920.6% in the 3rd quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock worth $167,000 after purchasing an additional 95,694 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in Regulus Therapeutics in the 3rd quarter worth about $204,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Regulus Therapeutics Trading Up 3.7 %

Shares of RGLS stock opened at $1.27 on Thursday. The stock has a market capitalization of $83.19 million, a P/E ratio of -1.19 and a beta of 1.60. The firm’s 50 day moving average is $1.52 and its 200 day moving average is $1.59. Regulus Therapeutics Inc. has a 12 month low of $1.08 and a 12 month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). On average, equities analysts predict that Regulus Therapeutics Inc. will post -0.88 EPS for the current year.

Insider Activity at Regulus Therapeutics

In other news, insider Preston Klassen sold 31,445 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $39,620.70. Following the transaction, the insider now owns 36,055 shares of the company’s stock, valued at $45,429.30. This represents a 46.59 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Christopher Ray Aker sold 38,547 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $48,569.22. Following the completion of the transaction, the vice president now directly owns 54,634 shares in the company, valued at $68,838.84. The trade was a 41.37 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 223,998 shares of company stock worth $282,237. 4.35% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a research report on Monday, November 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.80.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.